급성 초조 및 공격성 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Acute Agitation And Aggression Treatment Market size is expected to reach USD 8.97 Billion in 2034 from USD 5.42 Billion (2025) growing at a CAGR of 5.75% during 2026-2034.

The global acute agitation and aggression treatment market is growing steadily due to increasing awareness of mental health conditions and the need for effective management strategies. Acute agitation is commonly associated with psychiatric disorders, neurological conditions, and substance abuse, requiring immediate medical intervention. The demand for rapid-acting treatments has driven the development of specialized medications and therapies.

Key drivers include rising prevalence of mental health disorders, increased healthcare spending, and advancements in pharmacological treatments. The introduction of fast-acting injectable and inhalable medications has improved patient management in emergency settings. Additionally, growing efforts to reduce hospital stays and improve patient outcomes have contributed to market growth.

Looking ahead, the market is expected to witness continued expansion with the development of innovative therapies and personalized treatment approaches. Increased focus on mental healthcare infrastructure and early intervention strategies will further boost demand. As stigma surrounding mental health decreases, more patients are likely to seek treatment, supporting long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Approach

• Behavioral Approaches
• Environmental Interventions
• Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others)

By Indication

• Schizophrenia
• Dementia
• Bipolar Disorder
• Depression
• Drug-induced Agitation and Aggression
• Alcohol Withdrawal
• Others

By Route of Administration

• Oral
• Intramuscular
• Others

By End User

• Hospitals & Ambulatory Surgical Centers
• Psychiatric Care Facilities
• Others

COMPANIES PROFILED

• Eli Lilly And Company, , Pfizer Inc, Otsuka Holdings, GlaxoSmithKline, H Lundbeck AS, Johnson Johnson, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, F HoffmannLa Roche Ltd, Bausch Health Companies Inc, Apotex Inc, Aurobindo Pharma
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: BY TREATMENT APPROACH 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Approach
• 4.2. Behavioral Approaches Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Environmental Interventions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Schizophrenia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Bipolar Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Depression Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Drug-induced Agitation and Aggression Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Alcohol Withdrawal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals & Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Psychiatric Care Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment Approach
  • 8.2.2 By Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment Approach
  • 8.3.2 By Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment Approach
  • 8.4.2 By Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment Approach
  • 8.5.2 By Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment Approach
  • 8.6.2 By Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 Otsuka Holdings
  • 10.2.3 GlaxoSmithKline
  • 10.2.4 H. Lundbeck A/S
  • 10.2.5 Johnson & Johnson
  • 10.2.6 Teva Pharmaceutical Industries Ltd
  • 10.2.7 Amneal Pharmaceuticals LLC
  • 10.2.8 Sun Pharmaceutical Industries Ltd
  • 10.2.9 F. Hoffmann-La Roche Ltd
  • 10.2.10 Bausch Health Companies Inc
  • 10.2.11 Apotex Inc
  • 10.2.12 Aurobindo Pharma